Regeneration Biomedical, Inc. (RBI) is developing an investigational regenerative therapy designed to address the underlying biological processes associated with Alzheimer’s disease – not simply manage its symptoms.
Proprietary technology protected by U.S. patents.
Recognized by tghe DFA to support efficient development.
Phase 2s clinical trials are in progress.
Providing the capital and support to advance change.
Alzheimer’s disease affects more than memory. It gradually impacts independence, relationships, communication, and the very identity of the people our families love.
More than 6 million Americans live with Alzheimer’s disease, and that number is expected to double by 2050.
RBI’s investigational regenerative therapy is designed to act on the underlying biological processes associated with Alzheimer’s disease. Our goal is to explore whether a regenerative cellular approach may influence disease biology rather than only manage symptoms.
1
Cells are obtained from the patient.
2
3
4
Researchers evaluate safety, biomarkers, cognition, function, and other clinical outcomes.
RBI continues to advance its clinical program with the goal of exploring meaningful change in Alzheimer’s disease.
PFD Capital Partners is an Orange County-based investment firm that identifies and supports select medical technology companies. Our mission is to connect disciplined capital with innovative projects designed to produce meaningful human outcomes.
1
2
3
